Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10567572 
Yamamoto K, Ichijo H, Korsmeyer SJ (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19, 8469-78 10567572
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T69-p - Bcl-2 (human)
Orthologous residues
Bcl‑2 (human): T69‑p, Bcl‑2 (mouse): T69‑p, Bcl‑2 (rat): T69‑p
Characterization
 Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, peptide sequencing, phosphoamino acid analysis
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), WEHI-231 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase

S70-p - Bcl-2 (human)
Orthologous residues
Bcl‑2 (human): S70‑p, Bcl‑2 (mouse): S70‑p, Bcl‑2 (rat): S70‑p
Characterization
 Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, peptide sequencing, phosphoamino acid analysis
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), WEHI-231 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE JNK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JNK1 (human) transfection of dominant-negative enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited
 Effect of modification (process):  apoptosis, induced

S87-p - Bcl-2 (human)
Orthologous residues
Bcl‑2 (human): S87‑p, Bcl‑2 (mouse): S84‑p, Bcl‑2 (rat): S84‑p
Characterization
 Methods used to characterize site in vivo 2D analysis, [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, peptide sequencing, phosphoamino acid analysis
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte), WEHI-231 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE JNK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JNK1 (human) activation of upstream enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
taxol increase
Downstream Regulation
 Effect of modification (function):  activity, inhibited
 Effect of modification (process):  apoptosis, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.